Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2002
11/07/2002WO2002067857A3 Modified annexin proteins and methods for preventing thrombosis
11/07/2002WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002WO2002058775A3 Device for dilating and irradiating a vascular segment or body passageway
11/07/2002WO2002056827A3 Substituted felbamate derived compounds
11/07/2002WO2002056708A3 Preparation for improved dietary utilisation
11/07/2002WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002WO2002040030A8 Combination therapy for lowering and controlling intraocular pressure
11/07/2002WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002WO2002007732A3 Use of panaxatriol for stimulation angiogenesis
11/07/2002WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002WO2001048187A9 A molecular switch for regulating mammalian gene expression
11/07/2002WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002WO2001037859A3 Pharmaceutical compositions containing compounds which increase or decrease tmtnf levels
11/07/2002WO2001036365A3 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
11/07/2002WO2001034586A3 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
11/07/2002WO2001027305A9 Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms
11/07/2002WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002WO2000064420A3 Compositions and methods for treating amyloidosis using sulphonate derivatives
11/07/2002US20020166134 Cardiomyocytes with enhanced proliferative potenial, and methods for preparing and using same
11/07/2002US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002US20020165386 C-junction-n-terminal kinase (JNK); microbiocides; treating neurodegenerative diseases
11/07/2002US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002US20020165374 Secreted protein HFEAF41
11/07/2002US20020165351 Novel compounds
11/07/2002US20020165347 Polypeptide for use in the diagnosis, prevention and treatment of arteriosclerosis and vascular restenosis
11/07/2002US20020165282 PPAR agonists
11/07/2002US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002US20020165273 Carbamate compounds for use in preventing or treating neurodegenerative disorders
11/07/2002US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002US20020165252 Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation
11/07/2002US20020165247 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/07/2002US20020165240 Method of treating proliferative diseases using Eg5 inhibitors
11/07/2002US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002US20020165200 Central nervous system disorders
11/07/2002US20020165179 Multifunctional nanodevice platform
11/07/2002US20020165160 Fibroblast growth factor (FGF) mutein; treating coronary artery disease (atherosclerosis)
11/07/2002US20020165156 Tumor necrosis factor family and its blocking agent
11/07/2002US20020165155 Crystallization of IGF-1
11/07/2002US20020165154 Lipoprotein-regulating medicaments
11/07/2002US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002US20020165131 Histidine-rich glycoprotein
11/07/2002US20020164768 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of thrombosis and vascular system disorders
11/07/2002US20020164734 Human pelota homolog
11/07/2002US20020164719 Targeting pharmaceutical agents to injured tissues
11/07/2002US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002US20020164679 Polypeptides for use in the treatment of atherosclerosis and cardiovascular disorders
11/07/2002US20020164377 Mixture of retinoic acid and paclitaxel; polymeric carrier
11/07/2002US20020164355 Test to detect antibodies; calibration
11/07/2002US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002US20020164308 Embryonic stem cells and neural progenitor cells derived therefrom
11/07/2002US20020164301 Methods for inhibiting atherosclerotic plaque formation
11/07/2002US20020164287 Azo compounds for type i phototherapy
11/07/2002DE10120630A1 Pharmazeutische Zusammensetzung enthaltend Bulbophyllum A pharmaceutical composition comprising Bulbophyllum
11/07/2002CA2821193A1 Prevention of myocardial infarction induced ventricular expansion and remodeling
11/07/2002CA2594883A1 Pharmaceutically active uridine esters
11/07/2002CA2450018A1 Crystal of 6-[4-(4-pyridylamino)phenyl]-4, 5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate
11/07/2002CA2447748A1 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002CA2446083A1 Composition and methods for treatment of hyperplasia
11/07/2002CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002CA2445871A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002CA2445861A1 Pharmaceutically active uridine esters
11/07/2002CA2445860A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002CA2445811A1 Modified fvii in treatment of ards
11/07/2002CA2445702A1 Control of compactability through crystallization
11/07/2002CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002CA2445583A1 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4]dioxino[2,3-e]indole
11/07/2002CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002CA2445565A1 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002CA2445524A1 Stent-based delivery of statins to prevent restenosis
11/07/2002CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002CA2445338A1 G-protein coupled receptors
11/07/2002CA2445330A1 Potassium channel opener
11/07/2002CA2445298A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
11/07/2002CA2445294A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002CA2444500A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002CA2444499A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002CA2444429A1 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002CA2440775A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002CA2439943A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002WO2001084962A2 Compositions containing folic acid and reduced folate
11/06/2002EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002EP1254952A1 Cells capable of differentiating into heart muscle cells
11/06/2002EP1254904A1 Novel piperidine compounds and drugs containing the same
11/06/2002EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002EP1254895A1 Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
1 ... 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 ... 1595